A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

Conditions: Healthy Interventions: Drug: Pirtobrutinib; Drug: Placebo; Drug: Moxifloxacin Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials